CVS Caremark News

Drugstore chain Walgreen Co. has extended its agreement to fill prescriptions for CVS Caremark Corp., which runs one of the largest pharmacy benefits management businesses.

Chronic disease care costs the U.S. $1 trillion every year, according to a CVS Caremark survey.

Walgreens and CVS Caremark extended their agreement Monday, allowing patients to continue filling prescriptions at either of the popular drugstore chains.

A study conducted by researchers at CVS Caremark and Brigham and Women's Hospital and published in the May issue of the American Heart Journal found that non-white patients had 50% greater odds of statin medication non-adherence compared to white patients, while women had 10% greater odds of statin non-adherence compared to men.

To access the webcast, visit http://info.cvscaremark.com/investors . This webcast will be archived and available on the website for a one-year period following the presentation.

Larry Merlo had big shoes to fill when he took over as president and CEO of CVS Caremark in March 2011 from Tom Ryan, who had built the drugstore chain and become a leading business figure in Rhode Island.

Drugstore chain Walgreen Co. has extended its agreement to fill prescriptions for CVS Caremark Corp., which runs one of the nation's largest pharmacy benefit management businesses.

The companies are not disclosing the financial and other confidential terms of the agreement.

Homeshopping faces tough competition from internet retailing and has been losing sales to the more dynamic channel in past years.

The first quarter of 2013 saw plenty of dividend action from corporate America. According to Standard & Poor's, companies reported 944 dividend increases in the first quarter, paying out an additional $14.5 billion in dividends.

Summary: Over the past two years, investors have been favoring stocks that make their money inside the USA.

CVS Caremark today released its 2012 Corporate Social Responsibility Report, which gives stakeholders an inside view of the company's CSR strategy, priorities and performance on its sustainability goals and CSR initiatives.

Joseph is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

Then, the stock traded around $51 per share. Following its strong Q1 report, it now trades just below $59. Its trailing P/E is close to 20X.

's stock had its "neutral" rating restated by analysts at Goldman Sachs in a research report issued to clients and investors on Thursday, StockRatingsNetwork reports.

's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Thursday, Analyst Ratings Network.com reports.

The company has a stated goal of annually adding 2-3% to its total retail footprint, with a recent push towards urban format stores that focus on general merchandise and the convenience factor, planning to build nearly 100 of these in 2013.

CVS Caremark executives were upbeat during last week's conference call with analysts, as the company pulled in a "strong" first quarter and narrowed its 2013 guidance to reflect higher-than-expected performance.

Getting patients to take their medications as prescribed is an intractable problem costing the U.S. $290 billion a year according to a 2009 report by the New England Healthcare Institute.

Andrew Sussman, MD; Lisette Dunham, MSPH; Kristen Snower, MBA; Min Hu, MPH; Olga S. Matlin, PhD; William H. Shrank, MD; Niteesh K. Choudhry, MD, PhD; and Troyen Brennan, MD A propensity score matched-pair, cohort design was used to analyze healthcare spending patterns among CVS Caremark employees in the year following a visit to a MinuteClinic, the ... (more)